What Is Hexarelin? Benefits, Research & Safety
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
UK summary: Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.
Quick Facts
Overview
Hexarelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: Hexarelin is not approved by any regulatory authority. It is prohibited in sports by WADA. Available only as a research compound.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Most potent GHRP for biggest GH spike.
- Cardioprotective for athletes during heavy training.
- Safe long-term for body composition.
- Cleaner cortisol profile than GHRP-6.
07Common internet claims
- Marketed in bodybuilding and 'anti-ageing' stacks.
- Sold online as the most potent GHRP.
- Promoted for cardioprotection extrapolated from animal data.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cardioprotective for athletes / strength trainers” | D | No | High | Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established. |
| “Most potent GHRP — biggest GH spike” | C | Limited | High | Short-term studies show high GH-release potency; potency is not the same as clinical benefit. |
| “Use long-term for body composition” | E | No | High | Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Tachyphylaxis (diminishing effect) with chronic use.
- Cortisol and prolactin elevation.
- Water retention, joint pain, carpal tunnel symptoms.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains Hexarelin at the labelled concentration.
- Whether cardioprotective effects in animal studies translate to humans.
- What chronic use does to natural ghrelin signalling and hunger regulation.
- WADA detection windows — assume positive on test, strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- Cardiac outcome trials in humans absent.
- Phase 3 trials for any indication absent.
- Long-term safety unstudied.
- Combination-stack safety with CJC-1295, MK-677 uncharacterised.
19Safer alternatives / established care pathways
- Endocrinologist review for adult GH-deficiency with formal testing.
- Cardiac risk assessment and standard NHS cardioprotective interventions (statins, BP control, exercise).
- Licensed recombinant HGH under specialist supervision where confirmed deficiency.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Hexarelin a licensed UK medicine?
- What is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent growth hormone release (among the strongest GHRPs)
- 2Cardioprotective effects in research models
- 3Protection against ischemia-reperfusion injury
- 4Elevated IGF-1 levels
- 5Potential benefits for cardiac function
Claim vs Evidence
How popular claims about Hexarelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cardioprotective for athletes / strength trainers” | D | No | High | Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established. |
| “Most potent GHRP — biggest GH spike” | C | Limited | High | Short-term studies show high GH-release potency; potency is not the same as clinical benefit. |
| “Use long-term for body composition” | E | No | High | Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-200 mcg per dose |
| Frequency | 2-3 times daily (note: desensitisation may occur) |
| Duration | Often used in shorter cycles due to desensitisation |
| Notes | Hexarelin is not approved for therapeutic use. Desensitisation with repeated use may limit long-term effectiveness. Cycling or intermittent use may be considered. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Intravenous (research settings)
| Half-Life | Stability |
|---|---|
| Approximately 70 minutes (longer than some other GHRPs) | Lyophilised powder stable when properly stored |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Flushing
- Water retention
- Tingling or numbness
- Injection site reactions
- Cortisol elevation
Rare Risks & Concerns
- Desensitisation with chronic use
- Unknown long-term effects
- Effects on other hormonal axes
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Unstable cardiac conditions
- Diabetes (monitor closely)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Ghrelin shows no interaction with HEX, whereas it has a synergistical effect with GHRH on GH secretion. Thus, ghrelin is a new hormone playing a major role in the control of somatotroph secretion in humans, and its effects are imitated by nonnatural GHS.
Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.
These data suggest that either the hexarelin or desmopressin test can be used to differentiate patients with Cushing's disease from subjects with alcohol-dependent pseudo-Cushing's syndrome.
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-independent and might be mediated by specific GHS myocardial receptors.
The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
Our data suggest that the effect of GHSs on the HPA axis involve at least in part the stimulation of AVP release. In summary, we have shown that in healthy male volunteers, the effect of hexarelin on the HPA axis does not involve CRH, but may occur through the stimulation of AVP release.
Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Our results demonstrate that pyridostigmine is able to enhance the GH response only to a very low dose Hexarelin which, in turn, potentiates the GHRH-induced GH rise to the same extent as pyridostigmine. As there is evidence that GHRPs do not inhibit hypothalamic somatostatin release, these findings are consistent with the hypothesis that they act by antagonizing somatostatin activity and/or through unknown factors.
Registered Trials & Regulatory Status
1 of 3 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
NobelZygoma TiUltra Implant System Study
Status: Not Yet Recruiting · 85 participants · Nobel Biocare
Conditions: Edentulous Maxilla, Maxillary Bone Loss, Atrophic Maxilla
A PAC Post-Market Clinical Study to Demonstrate Color Change in the WoundCue™ Kit When an Elevated Inhibitory Bacterial and/or Fungal Load is Present in a Wound
Status: Not Yet Recruiting · 50 participants · ParaNano, Inc.
Conditions: Wound Care
Effect of Heated Water-Based Versus Land-Based Exercise Training on Hemodynamic Variables, Functional Capacity and Quality of Life in Older Hypertensive
Status: Recruiting · 60 participants · Universidade Estadual Paulista Júlio de Mesquita Filho
Conditions: Hypertension, Aging, Exercise
Home Exercise Program for Homebound Older Adults
Status: Completed · 19 participants · University of Maryland, Baltimore
Conditions: Aging
Short Dental Implants (5 mm) Versus Long Dental Implants (10 mm)
Status: Completed · 34 participants · University of Michigan
Conditions: Bone Loss, Alveolar
An Implant With an Acid-etched Fixture Surface and Internal-hex Collar May Achieve Greater Osseointegration.
Status: Completed · 58 participants · Université de Montréal
Conditions: Jaw, Edentulous, Dental Implant
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Hexarelin?
Source research-grade Hexarelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Hexarelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Hexarelin a licensed UK medicine?
- What is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn more